Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2329793 | 0.90 | SCNN1A (0.53) | SCNN1A | |
| SCHEMBL938310 | 0.89 | SCNN1A (0.43) | SCNN1A | |
| SCHEMBL2329956 | 0.88 | SCNN1A (0.47) | SCNN1AKCNH2 | |
| SCHEMBL2286255 | 0.87 | SCNN1A (0.51) | SCNN1A | |
| SCHEMBL10028721 | 0.85 | SCNN1A (0.57) | SCNN1AKCNH2 | |
| SCHEMBL14268265 | 0.85 | SCNN1A (0.59) | SCNN1AKCNH2 | |
| SCHEMBL17809354 | 0.85 | SCNN1A (0.59) | SCNN1A | |
| SCHEMBL16572343 | 0.85 | SCNN1A (0.51) | SCNN1AKCNH2 | |
| SCHEMBL12908911 | 0.85 | SCNN1A (0.48) | SCNN1A | |
| SCHEMBL9913778 | 0.85 | SCNN1A (0.60) | SCNN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062308-A1 | METHODS OF USING SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-20060142306-A1 | Bronchodilator agents; respiratory system disorders; skin disorders ; asthma; hypotensive agents | CYFI, INC. (US) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142306-A1 | Bronchodilator agents; respiratory system disorders; skin disorders ; asthma; hypotensive agents | ADRB2, ADRB3, ADRA1D | SCNN1A 92/4885KCNH2 63/4885 |
| US-20090062308-A1 | METHODS OF USING SODIUM CHANNEL BLOCKERS | SCN1B, KCNN3, SCN2B | SCNN1A 30/4885KCNH2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.